Melatonin Research: What Published Studies Have Investigated

What is melatonin?

What is melatonin? It is an indoleamine — chemically N-acetyl-5-methoxytryptamine, formula C₁₃H₁₆N₂O₂, molecular weight about 232.3. It is a small molecule and not a peptide, so the sequence row used on every peptide page in this library does not apply and has been omitted rather than filled with something inapplicable.

Structurally it is a tryptamine: an indole ring with an ethylamine side chain, carrying a 5-methoxy group on the ring and an N-acetyl group on the side chain. Both of those substituents are added enzymatically to serotonin, which makes melatonin a direct two-step metabolic descendant of a neurotransmitter. It is amphiphilic — soluble in lipids and, more modestly, in water — which is why it distributes readily across membranes and compartments.

Functionally it is a hormone, produced chiefly by the pineal gland with a strong daily rhythm: low in daylight, rising in darkness. That rhythm, rather than the molecule’s presence, is what the circadian literature is about, and it is the reason melatonin is described in the research literature as a timing signal. Cipolla-Neto and Amaral’s Endocrine Reviews article (2018, PMID 30215696) is the standard modern synthesis of melatonin’s hormonal physiology.

Discovery and origin in the literature

A pigment assay in a dermatology laboratory

Melatonin was found by Aaron Lerner’s group at Yale in the late 1950s, in a search for a pineal factor that lightened amphibian skin — the name comes from its action on melanophores plus its serotonin lineage. Lerner, Case and Takahashi published the isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands in the Journal of Biological Chemistry in 1960 (PMID 14415935). It took the processing of enormous quantities of pineal tissue to obtain the material, which is worth remembering when reading how casually the molecule is treated today.

The enzyme that makes the rhythm

The second foundational thread is enzymology. Arylalkylamine N-acetyltransferase (AANAT) catalyses the acetylation of serotonin, the penultimate and rate-controlling step of melatonin synthesis, and its activity varies dramatically across the day-night cycle. David Klein — whose laboratory did much of the work — named it “the Timezyme” in a 2007 Journal of Biological Chemistry review (PMID 17164235). The name captures the point precisely: the rhythm in melatonin output is generated by a rhythm in enzyme activity, driven by the suprachiasmatic nucleus and suppressed by light reaching the retina.

Receptors, named properly

The receptor pharmacology was formalised by the International Union of Basic and Clinical Pharmacology. Dubocovich, Delagrange, Krause, Sugden, Cardinali and Olcese (2010, Pharmacological Reviews, PMID 20605968) set out the nomenclature, classification and pharmacology of the G protein-coupled melatonin receptors MT₁ and MT₂. Structural biology followed much later; Okamoto, Cecon, Nureki, Rivara and Jockers reviewed melatonin receptor structure and signalling in the Journal of Pineal Research in 2024 (PMID 38587234).

Reference data

Values from the public chemical record (PubChem CID 896). Identity and physical form only.

Light protection is not boilerplate for this compound — the indole chromophore is photosensitive, which is a genuine stability consideration for stored material. No handling, dilution or reconstitution guidance is given anywhere on this page, and no route or quantity is stated or implied.

Mechanisms researchers have examined

The melatonin mechanism literature has a well-defined receptor core and a much looser periphery. Both are described here, and the difference between them is stated:

• MT₁ and MT₂ receptor signalling — two high-affinity G protein-coupled receptors, predominantly G_i-coupled with inhibition of adenylyl cyclase among the characterised outputs. Their nomenclature and pharmacology are formalised in the IUPHAR review (Dubocovich 2010); their structures and signalling are reviewed by Okamoto and colleagues (2024).
• Receptor expression in the suprachiasmatic nucleus — melatonin receptors in the SCN are the anatomical basis for the feedback loop in which the clock drives melatonin synthesis and melatonin in turn acts on the clock. This is the mechanistic substrate of the phase-response work below.
• AANAT as the rhythm-generating step — Klein’s “Timezyme” account (2007) places the day-night variation in the enzyme rather than in substrate availability, with retinal light input suppressing the nocturnal rise.
• Extra-pineal synthesis and non-receptor chemistry — melatonin is also produced outside the pineal gland, and a large literature examines direct chemical interactions with reactive species independent of MT₁/MT₂. Cipolla-Neto and Amaral (2018) review this breadth. It is worth naming plainly that the concentrations used in many in-vitro studies of this kind are orders of magnitude above physiological plasma concentrations, which limits what those experiments can support.
• Short and variable elimination — exogenous melatonin is cleared rapidly, principally by hepatic 6-hydroxylation with wide between-individual variation. This pharmacokinetic fact is one reason trial results in this field are heterogeneous.

Research findings by area

Circadian phase-shifting and the phase-response curve

This is the strongest and most distinctive part of the melatonin literature, and it is methodological rather than clinical. Lewy, Ahmed, Jackson and Sack (1992, Chronobiology International, PMID 1394610) reported that melatonin shifts human circadian rhythms according to a phase-response curve — the size and direction of the shift depend on the circadian time at which it is given, not simply on whether it is given. Lewy, Bauer, Ahmed and colleagues (1998, PMID 9493716) reported that the human phase-response curve to melatonin is approximately 12 hours out of phase with the phase-response curve to light.

That second finding is elegant and is genuinely established chronobiology: light and melatonin move the human clock in opposite directions at the same circadian times, consistent with melatonin being the internal darkness signal. It is reported here as circadian-research methodology. It is not advice, and no timing, quantity or protocol appears anywhere on this page.

The sleep meta-analyses, read honestly

Two pooled analyses are cited here because reading either alone gives a distorted picture. Buscemi, Vandermeer, Hooton and colleagues (2006, BMJ, PMID 16473858) examined the efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction. Ferracioli-Oda, Qawasmi and Bloch (2013, PLoS One, PMID 23691095) pooled randomised trials of melatonin in primary sleep disorders.

What is fair to say about this body of work, and all this page says about it: the trials are numerous, generally small, methodologically heterogeneous in population, formulation and timing, and the pooled effects reported in this literature are modest. Cellworks makes no claim in its own voice about any sleep-related outcome, and nothing on this page should be read as one. The compound is catalogued here as a research chemical.

The analytical literature on melatonin products

This section is unusual for a compound page and it belongs on this one specifically, because melatonin is the compound in this catalogue most likely to be encountered as a consumer product — and the peer-reviewed analyses of those products are unflattering.

Erland and Saxena (2017, Journal of Clinical Sleep Medicine, PMID 27855744) analysed melatonin natural health products and supplements, reporting significant variability in melatonin content relative to label and the presence of serotonin in some samples — a contaminant of a quite different pharmacological character. Cohen, Avula, Wang, Katragunta and Khan (2023, JAMA, PMID 37097362) analysed melatonin gummies sold in the United States and reported discrepancies between labelled and measured quantities of melatonin, and also examined CBD content.

The general point generalises well beyond melatonin: a label is a claim, and a certificate of analysis for the specific batch is a measurement. That distinction is the entire premise of how material is documented here.

Research models and evidence status

What is well established

The chemistry and biosynthetic route; AANAT’s rate-controlling role and the light-suppressible nocturnal rhythm; the existence, nomenclature and pharmacology of MT₁ and MT₂; and the human circadian phase-response curve and its relationship to the light phase-response curve. These rest on decades of independent replication.

What is not established

Far more than the popular framing suggests. The size and clinical meaning of any sleep-related effect remains contested across heterogeneous trials, and this page takes no position on it. The high-concentration in-vitro literature on non-receptor chemistry has not been shown to correspond to anything at physiological concentrations in people. Long-term effects of chronic exogenous administration, particularly in developing populations, are not characterised in the published record. And the content and identity of any given commercial melatonin product cannot be assumed from its label, as the two analytical papers above demonstrate directly.

This page makes no efficacy, therapeutic, sleep-related, circadian, antioxidant or other use claim of any kind. Every finding above is attributed to the investigators who reported it. The material catalogued here is supplied for laboratory research use only — not for human or veterinary use, and not as a dietary supplement.

Adjacent compounds in this library

Two other catalogued compounds sit in the sleep and circadian research space and are covered on their own pages rather than restated here: DSIP, the delta sleep-inducing peptide, whose literature is far thinner and older than melatonin’s; and Epitalon, a synthetic tetrapeptide studied largely by a single research group in relation to pineal function. Melatonin differs from both in kind: it is an endogenous hormone with a large independent, international literature, which is precisely why its unresolved questions are so clearly visible.

How to verify this compound yourself

Melatonin is a small molecule, and the verification workflow departs from the peptide one in several specific ways:

• No sequence to confirm — peptide certificates rest on matching a sequence to an expected mass. For an indoleamine there is no sequence; identity rests on the structure, confirmed by NMR, infrared spectroscopy, or chromatographic comparison against a certified reference standard.
• HPLC-UV purity, and what the impurities are — the indole chromophore gives a strong UV signal, so reversed-phase HPLC with UV detection is the routine purity method. The impurities that matter are the biosynthetic and degradation neighbours: N-acetylserotonin, serotonin itself, and 5-methoxytryptamine. Erland and Saxena’s finding of serotonin in commercial products is exactly the class of contaminant a proper related-substances method is designed to catch.
• Pharmacopoeial monographs exist — unlike most compounds in this catalogue, melatonin is covered by pharmacopoeial monographs specifying identity and related-substance limits. A certificate referencing a recognised monograph method is materially more informative than one reporting a bare percentage.
• Water content and residual solvents — the routine small-molecule specification lines, in place of the counter-ion and endotoxin lines that dominate peptide certificates. Endotoxin testing is not a standard small-molecule specification and its absence is not a red flag here.
• Light-protected handling as a stability question — the chromophore that makes UV detection easy also makes the material photosensitive, so storage conditions bear on later analysis.

See how to read a COA for what each certificate line means, and how to verify peptide purity for the peptide workflow this compound departs from. The exact batch received can be checked on the self-serve verify tool.

Research-grade sourcing and verification

Melatonin is not held in stock. It appears on our sourcing catalogue as available to order — our supplier lists it, we have not bought it, and material of this kind typically takes about two to three weeks to reach us. For laboratory research use only, it is supplied with a per-batch Certificate of Analysis reporting purity and identity confirmation, verifiable at the lot level. It is not supplied as a food, a dietary supplement or a medicine, and the published product analyses cited above are the reason batch-level documentation is the standard applied here. For the adjacent sleep and circadian research compounds, see DSIP research and Epitalon research. This is sourcing and quality-assurance framing only.

Frequently asked questions

Literature cited

1. Lerner AB, Case JD, Takahashi Y. “Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands.” Journal of Biological Chemistry. 1960;235:1992–1997. PMID 14415935. pubmed.ncbi.nlm.nih.gov/14415935.
2. Klein DC. “Arylalkylamine N-acetyltransferase: ‘the Timezyme’.” Journal of Biological Chemistry. 2007;282(7):4233–4237. PMID 17164235. pubmed.ncbi.nlm.nih.gov/17164235.
3. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. “International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.” Pharmacological Reviews. 2010;62(3):343–380. PMID 20605968. pubmed.ncbi.nlm.nih.gov/20605968.
4. Okamoto HH, Cecon E, Nureki O, Rivara S, Jockers R. “Melatonin receptor structure and signaling.” Journal of Pineal Research. 2024;76(3):e12952. PMID 38587234. pubmed.ncbi.nlm.nih.gov/38587234.
5. Lewy AJ, Ahmed S, Jackson JM, Sack RL. “Melatonin shifts human circadian rhythms according to a phase-response curve.” Chronobiology International. 1992;9(5):380–392. PMID 1394610. pubmed.ncbi.nlm.nih.gov/1394610.
6. Lewy AJ, Bauer VK, Ahmed S, Thomas KH, Cutler NL, Singer CM. “The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light.” Chronobiology International. 1998;15(1):71–83. PMID 9493716. pubmed.ncbi.nlm.nih.gov/9493716.
7. Cipolla-Neto J, Amaral FGD. “Melatonin as a Hormone: New Physiological and Clinical Insights.” Endocrine Reviews. 2018;39(6):990–1028. PMID 30215696. pubmed.ncbi.nlm.nih.gov/30215696.
8. Buscemi N, Vandermeer B, Hooton N, et al. “Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis.” BMJ. 2006;332(7538):385–393. PMID 16473858. pubmed.ncbi.nlm.nih.gov/16473858.
9. Ferracioli-Oda E, Qawasmi A, Bloch MH. “Meta-analysis: melatonin for the treatment of primary sleep disorders.” PLoS One. 2013;8(5):e63773. PMID 23691095. pubmed.ncbi.nlm.nih.gov/23691095.
10. Erland LA, Saxena PK. “Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content.” Journal of Clinical Sleep Medicine. 2017;13(2):275–281. PMID 27855744. pubmed.ncbi.nlm.nih.gov/27855744.
11. Cohen PA, Avula B, Wang YH, Katragunta K, Khan I. “Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US.” JAMA. 2023;329(16):1401–1402. PMID 37097362. pubmed.ncbi.nlm.nih.gov/37097362.
12. National Center for Biotechnology Information. “PubChem Compound Summary for CID 896, Melatonin.” pubchem.ncbi.nlm.nih.gov/compound/896 (formula, mass, CAS 73-31-4).